PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1615989
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1615989
Dipeptidyl Peptidase 4 Inhibitors Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032
The Global Dipeptidyl Peptidase 4 Inhibitors Market was valued at USD 11.3 billion in 2023 and is expected to grow at a CAGR of 3.5% during the forecast period. The market expansion is largely driven by the increasing prevalence of type 2 diabetes worldwide, boosting demand for effective treatments. DPP-4 inhibitors are becoming a preferred choice for managing type 2 diabetes due to their ability to regulate blood sugar levels without causing significant side effects such as weight gain or hypoglycemia. These inhibitors work by preventing hormones' breakdown, which stimulates insulin release in response to meals.
Advancements in drug development and new formulations are also contributing to the market's growth. Pharmaceutical companies are focusing on creating DPP-4 inhibitors that offer better efficacy and safety, with innovations like longer-lasting formulations to improve patient adherence. There is also an emerging trend toward combination therapies that include DPP-4 inhibitors alongside other antidiabetic drugs, offering a more comprehensive approach to managing blood sugar. In terms of drug types, the market is divided into saxagliptin, sitagliptin, linagliptin, alogliptin, vildagliptin, and others.
In 2023, sitagliptin held the largest market share, accounting for 40.4%. Its long history of effectiveness in managing blood glucose, combined with its wide availability and established brand presence, has helped solidify its dominance. The market is further categorized by medication type, with branded and generic DPP-4 inhibitors. The branded segment was worth USD 7.9 billion in 2023 and leads the market due to extensive clinical trials supporting the efficacy and safety of branded drugs.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $11.3 Billion |
| Forecast Value | $15.2 Billion |
| CAGR | 3.5% |
This segment benefits from strong distribution networks and trust among healthcare providers and patients. When it comes to distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are expected to grow at a CAGR of 3.4%, driven by the increasing need for specialized diabetes care. North America dominated the global market, accounting for USD 4.6 billion in 2023. The region's market is projected to grow at a 3.4% CAGR, fueled by the rising incidence of type 2 diabetes, high obesity rates, and well-established healthcare infrastructure, especially in the U.S., where demand for DPP-4 inhibitors continues to rise.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of type 2 diabetes
- 3.2.1.2 High patient preference for oral medications
- 3.2.1.3 Increasing combination therapy trend
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Availability of other antidiabetic drugs
- 3.2.2.2 Side effects associated with DPP-4 inhibitors
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Sitagliptin
- 5.3 Saxagliptin
- 5.4 Linagliptin
- 5.5 Alogliptin
- 5.6 Vildagliptin
- 5.7 Other drug types
Chapter 6 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Branded
- 6.3 Generic
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacies
- 7.3 Retail pharmacies
- 7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AstraZeneca plc
- 9.2 Bristol Myers Squibb Company
- 9.3 Boehringer Ingelheim International GmbH
- 9.4 Eli Lilly and Company
- 9.5 Merck & Co., Inc.
- 9.6 Mitsubishi Tanabe Pharma Corporation
- 9.7 Novartis AG
- 9.8 Pfizer, Inc.
- 9.9 Takeda Pharmaceuticals Company Limited
- 9.10 Sanofi
- 9.11 Sanwa Kagaku Kenkyusho Co., Ltd.
